1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. JNK

JNK

c-Jun N-terminal kinase

JNK (c-Jun N-terminal kinase), a kinase subfamily belonging to the MAPK, is activated in response to various stress stimuli and possesses a wide variety of regulatory functions. The JNK family of serine/threonine protein kinases comprises three isoforms (JNK1, JNK2 and JNK3). JNKs are involved in the emergence and progression of diverse pathologies such as neurodegenerative, cardiovascular and metabolic disorders as well as inflammation and cancer.

Similar to the other MAP kinases, JNKs are activated by a phosphorylation cascade generally involving two types of upstream kinases, the so-called MAP kinase kinase kinases (MAP3K, MKKK) and the MAP kinase kinases (MAP2K; MKK). At the MAP2K level, JNKs are activated by MKK4 and MKK7, the former is a common activator of the JNK and the p38 MAP kinase signaling pathway. The JNK cascade shares various intersection points with other pathways making it a part of a complex signaling network.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-150688
    JAK3-IN-13
    Inhibitor
    JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity.
    JAK3-IN-13
  • HY-151430
    Nrf2/HO-1 activator 1
    Inducer
    Nrf2/HO-1 activator 1 (Compound 24) is a potent Nrf2/HO-1 activator, neuroprotective agent. Nrf2/HO-1 activator 1 shows neuroprotective and antioxidant activities. Nrf2/HO-1 activator 1 can be used in Parkinson's disease (PD) research.
    Nrf2/HO-1 activator 1
  • HY-N12561
    Pestanoid A
    Inhibitor
    Pestanoid A is a rearranged pimarane diterpenoid osteoclastogenesis inhibitor with an IC50 of 4.2 μM. Pestanoid A can be isolated from the marine mesophotic zone chalinidae sponge-associated fungus, Pestalotiopsis sp. NBUF145. Pestanoid A inhibits the receptor activator of NF-kB ligand-induced MAPK and NF-κB signaling by suppressing the phosphorylation of ERK1/2-JNK1/2-p38 MAPKs and NF-κB nuclear translocation. Pestanoid A can be used for the study of osteoporosis.
    Pestanoid A
  • HY-N19215
    Arnicolide B
    Inhibitor
    Arnicolide B is a sesquiterpene lactone. Arnicolide B is isolated from Centipeda minima. Arnicolide B inhibits the phosphorylation of ERK, JNK and p38 proteins in the MAPK signaling pathway. Arnicolide B reduces the production of inflammatory mediators NO, PGE2 and IL-6. Arnicolide B downregulates the overexpression of inflammatory proteins iNOS and COX-2. Arnicolide B has no effect on IκB-α degradation or NF-κB pathway activation. Arnicolide B is applicable to inflammation-related research.
    Arnicolide B
  • HY-RS08127
    MAPK9 Human Pre-designed siRNA Set A
    Inhibitor

    MAPK9 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAPK9 Human Pre-designed siRNA Set A
  • HY-179033
    Nur77 antagonist 2
    Activator
    Nur77 antagonist 2 (Compound 12b) is an orally active Nur77 antagonist with a KD value of 0.42 μM. Nur77 antagonist 2 exhibits proliferative activity on liver cancer cells. Nur77 antagonist 2 stabilizes Nur77 by inhibiting its ubiquitin-proteasomal degradation, leading to Nur77-dependent apoptosis via the ASK1-JNK/p38 pathway. Nur77 antagonist 2 inhibits tumor growth in the HCCLM3 xenograft model. Nur77 antagonist 2 can be used for the study of hepatocellular carcinoma (HCC).
    Nur77 antagonist 2
  • HY-169736
    JNK-IN-21
    Inhibitor
    JNK-IN-21 (Compound 62) is a JNK-1 inhibitor.
    JNK-IN-21
  • HY-136602
    MT-21
    Activator
    MT-21 is an Apoptosis inducer and adenine nucleotide translocase inhibitor. MT-21 induces Apoptosis by activating JNK via the Krs/MST protein. MT-21 activates caspase-3 via caspase-9. MT-21 induces the release of cytochrome c. MT-21 can be used in the research of tumors.
    MT-21
  • HY-N0589S
    Dehydrodiisoeugenol-d4
    Inhibitor
    Dehydrodiisoeugenol-d4 is the deuterium labeled Dehydrodiisoeugenol (HY-N0589). Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis.
    Dehydrodiisoeugenol-d<sub>4</sub>
  • HY-119831
    Rohitukine
    Inhibitor
    Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM. Rohitukine blocks ATP binding sites of CDK2/A and CDK9/T1, suppresses PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling, and increases hepatic LXRα expression. Rohitukine induces S-phase cell cycle arrest, ROS generation, apoptosis, and exhibits anti-inflammatory activity. Rohitukine can be used for the research of leukemia, pancreatic cancer, prostate cancer, breast cancer, CNS cancer, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis.
    Rohitukine
  • HY-155077
    JNK-IN-12
    Inhibitor
    JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125 (HY-12041). JNK-IN-12 doesn't inhibit nuclear JNK signaling, but does inhibit mitochondrial JNK phosphorylation. JNK-IN-12 helps to improve the Parkinson's disease (PD) both in vitro and in vivo.
    JNK-IN-12
  • HY-149485
    JNK2-IN-1
    Inhibitor
    JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 μM). JNK2-IN-1 has anti-inflammatory activity. JNK2-IN-1 decreases the release of TNF-α and IL-6 through inhibiting the activation of NF-κB/MAPK pathway. JNK2-IN-1 alleviates the symptoms of LPS-induced acute lung injury (ALI) and sepsis.
    JNK2-IN-1
  • HY-P3395A
    Catestatin sCst
    Control
    Catestatin sCst is a negative control peptide with a scrambled amino acid sequence. Catestatin sCst fails to activate human mast cells and is used to verify the specificity of Catestatin action.
    Catestatin sCst
  • HY-N6908R
    Continentalic acid (Standard)
    Modulator
    Continentalic acid (Standard) is the analytical standard of Continentalic acid (HY-N6908). This product is intended for research and analytical applications. Continentalic acid is a diterpenoid organic acid. Continentalic acid exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial and antitumor effects. Continentalic acid alleviates oxidative stress, reduces pro-inflammatory cytokine production, inhibits MAPK phosphorylation and neutrophil infiltration, and induces growth inhibition and apoptosis of cancer cells. Continentalic acid can be used in research related to traumatic brain injury, cancer, inflammation and infections.
    Continentalic acid (Standard)
  • HY-172198
    GSK3-IN-10
    Inhibitor
    GSK3-IN-10 (Compound 4) is a multi-target inhibitor, that mainly targets GSK3α and GSK3β with IC50 of 1.0 nM and 2.0 nM. GSK3-IN-10 inhibits the activation of β-catenin, promotes the neuronal survival, and exhibits a protective effect against endoplasmic reticulum stress.
    GSK3-IN-10
  • HY-N2026AR
    Propylparaben sodium (Standard)
    Propylparaben (Propyl parahydroxybenzoate) sodium (Standard) is the analytical standard of Propylparaben sodium (HY-N2026A). Propylparaben (Propyl parahydroxybenzoate) sodium is an antibacterial preservative that can be produced by plants and bacteria. Propylparaben sodium is an orally active weak estrogen receptor agonist. Propylparaben sodium regulates the PI3K-AKT and JNK signaling pathways, and induces oxidative stress. Propylparaben sodium is commonly used in cosmetics, pharmaceuticals and foods, and can be used in studies related to ovarian aging and myocardial ischemia-reperfusion injury.
    Propylparaben sodium (Standard)
  • HY-P10076
    TAT-JBD20
    Inhibitor
    TAT-JBD20 (L-HIV-TAT(48–57)-PP-JBD20) is a JNK peptide inhibitor. TAT-JBD20 can be used for research of diabetes.
    TAT-JBD20
  • HY-181812
    JNK2/MKK7 PPI-IN-1
    Inhibitor
    JNK2/MKK7 PPI-IN-1 is an orally active JNK2 inhibitor with an IC50 of 0.99 μM and a Kd of 81.6 μM. JNK2/MKK7 PPI-IN-1 inhibits JNK2 kinase activity, disrupts JNK2-MKK7 protein-protein interaction, and reduces c-Jun phosphorylation. JNK2/MKK7 PPI-IN-1 inhibits LPS-induced overexpression of inflammatory cytokines IL-6 and TNF-α. JNK2/MKK7 PPI-IN-1 can be used for the research of acute lung injury.
    JNK2/MKK7 PPI-IN-1
  • HY-P11183
    Cathelicidin-PY
    Inhibitor
    Cathelicidin-PY is an antimicrobial peptide exhibiting strong antimicrobial property. Cathelicidin-PY inhibits the activation of TLR4 inflammatory response pathways induced by lipopolysaccharide (LPS) (HY-D1056). Cathelicidin-PY possesses strong antimicrobial and anti-inflammatory activities and low cytotoxic ability against RAW 264.7 cells. Cathelicidin-PY can be used for antimicrobial and anti-inflammatory research.
    Cathelicidin-PY
  • HY-179248
    Adenosine receptor antagonist 7
    Inhibitor
    Adenosine receptor antagonist 7 is an orally active triple A1/A2A/A2B adenosine receptor antagonist with Ki values of 1.5, 0.6 and 21 nM. Adenosine receptor antagonist 7 shows potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells. Adenosine receptor antagonist 7 can enhance infiltration of effector T cells and increase the CD8+/Treg ratio companied with Avelumab (HY-108730). Adenosine receptor antagonist 7can be used for the research of cancer, such as colon cancer.
    Adenosine receptor antagonist 7
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.